Cardiol Therapeutics to Webcast AGM Amidst Ongoing Clinical Trials

The latest update is out from Cardiol Therapeutics ( (TSE:CRDL) ).

Cardiol Therapeutics announced that its virtual Annual General Meeting of Shareholders will be webcast on May 28, 2025. The company is actively advancing its clinical trials, including the Phase III MAVERIC trial for recurrent pericarditis and the Phase II ARCHER trial for acute myocarditis. These efforts, supported by the US FDA’s Orphan Drug Designation for CardiolRx™ in pericarditis, aim to enhance Cardiol’s position in the heart disease treatment market.

The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.

Spark’s Take on TSE:CRDL Stock

According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.

Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.

To see Spark’s full report on TSE:CRDL stock, click here.

More about Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Their lead product, CardiolRx™, is a cannabidiol oral solution in clinical development for treating heart conditions such as myocarditis and pericarditis. The company is also working on CRD-38, a novel drug formulation for heart failure.

Average Trading Volume: 85,374

Technical Sentiment Signal: Sell

Current Market Cap: C$125.6M

See more insights into CRDL stock on TipRanks’ Stock Analysis page.